Published in J Clin Oncol on November 02, 2015
A whole-genome sequence and transcriptome perspective on HER2-positive breast cancers. Nat Commun (2016) 0.88
Role of TP53 mutations in triple negative and HER2-positive breast cancer treated with neoadjuvant anthracycline/taxane-based chemotherapy. Oncotarget (2016) 0.82
Nanoparticle albumin-bound paclitaxel as neoadjuvant chemotherapy of breast cancer: a systematic review and meta-analysis. Oncotarget (2017) 0.79
The efficiency and safety of trastuzumab and lapatinib added to neoadjuvant chemotherapy in Her2-positive breast cancer patients: a randomized meta-analysis. Onco Targets Ther (2016) 0.78
Impact of neoadjuvant therapy on eligibility for and frequency of breast conservation in stage II-III HER2-positive breast cancer: surgical results of CALGB 40601 (Alliance). Breast Cancer Res Treat (2016) 0.77
Looking Deep Into the Heterogeneity of Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer: Can We Understand It Better? J Clin Oncol (2016) 0.77
A phenotypic and mechanistic perspective on heterogeneity of HER2-positive breast cancers. Mol Cell Oncol (2016) 0.75
Impact of race, ethnicity, and BMI on achievement of pathologic complete response following neoadjuvant chemotherapy for breast cancer: a pooled analysis of four prospective Alliance clinical trials (A151426). Breast Cancer Res Treat (2016) 0.75
Effects of lapatinib or trastuzumab, alone and in combination, in human epidermal growth factor receptor 2-positive breast cancer: a meta-analysis of randomized controlled trials. Cancer Med (2016) 0.75
RNA Sequencing to Predict Response to Neoadjuvant Anti-HER2 Therapy: A Secondary Analysis of the NeoALTTO Randomized Clinical Trial. JAMA Oncol (2016) 0.75
Resistance to therapy in estrogen receptor positive and human epidermal growth factor 2 positive breast cancers: progress with latest therapeutic strategies. Ther Adv Med Oncol (2016) 0.75
Recent Advances in the Neoadjuvant Treatment of Breast Cancer. J Breast Cancer (2017) 0.75
Neoadjuvant Therapy for Breast Cancer: Established Concepts and Emerging Strategies. Drugs (2017) 0.75
Neoadjuvant buparlisib plus trastuzumab and paclitaxel for women with HER2+ primary breast cancer: A randomised, double-blind, placebo-controlled phase II trial (NeoPHOEBE). Eur J Cancer (2017) 0.75
Axillary Management of Stage II/III Breast Cancer Patients Treated with Neoadjuvant Systemic Therapy: Results of CALGB 40601 (HER2-positive) and CALGB 40603 (Triple-negative). J Am Coll Surg (2017) 0.75
HER2-positive breast cancer is lost in translation: time for patient-centered research. Nat Rev Clin Oncol (2017) 0.75
Accrual of Older Patients With Breast Cancer to Alliance Systemic Therapy Trials Over Time: Protocol A151527. J Clin Oncol (2016) 0.75
Unmet Needs in Clinical Research in Breast Cancer: Where Do We Need to Go? Clin Cancer Res (2017) 0.75
Molecular portraits of human breast tumours. Nature (2000) 94.14
American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12
Supervised risk predictor of breast cancer based on intrinsic subtypes. J Clin Oncol (2009) 22.22
Comprehensive genomic characterization of squamous cell lung cancers. Nature (2012) 18.90
Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med (2011) 12.45
A functional genetic approach identifies the PI3K pathway as a major determinant of trastuzumab resistance in breast cancer. Cancer Cell (2007) 11.21
PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients. Cancer Cell (2004) 10.89
Identification of conserved gene expression features between murine mammary carcinoma models and human breast tumors. Genome Biol (2007) 10.49
Lapatinib with trastuzumab for HER2-positive early breast cancer (NeoALTTO): a randomised, open-label, multicentre, phase 3 trial. Lancet (2012) 7.31
Efficacy and safety of neoadjuvant pertuzumab and trastuzumab in women with locally advanced, inflammatory, or early HER2-positive breast cancer (NeoSphere): a randomised multicentre, open-label, phase 2 trial. Lancet Oncol (2011) 7.10
Breast cancer molecular profiling with single sample predictors: a retrospective analysis. Lancet Oncol (2010) 6.88
Estrogen-regulated genes predict survival in hormone receptor-positive breast cancers. J Clin Oncol (2006) 4.84
Tumor infiltrating lymphocytes are prognostic in triple negative breast cancer and predictive for trastuzumab benefit in early breast cancer: results from the FinHER trial. Ann Oncol (2014) 3.80
EGFR associated expression profiles vary with breast tumor subtype. BMC Genomics (2007) 3.35
Loss of phosphatase and tensin homolog or phosphoinositol-3 kinase activation and response to trastuzumab or lapatinib in human epidermal growth factor receptor 2-overexpressing locally advanced breast cancers. J Clin Oncol (2010) 2.93
Preoperative chemotherapy plus trastuzumab, lapatinib, or both in human epidermal growth factor receptor 2-positive operable breast cancer: results of the randomized phase II CHER-LOB study. J Clin Oncol (2012) 2.76
Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol (2012) 2.75
Pathological complete response and accelerated drug approval in early breast cancer. N Engl J Med (2012) 2.69
Gene expression patterns associated with p53 status in breast cancer. BMC Cancer (2006) 2.61
Lapatinib as a component of neoadjuvant therapy for HER2-positive operable breast cancer (NSABP protocol B-41): an open-label, randomised phase 3 trial. Lancet Oncol (2013) 2.59
Genomic analysis reveals that immune function genes are strongly linked to clinical outcome in the North Central Cancer Treatment Group n9831 Adjuvant Trastuzumab Trial. J Clin Oncol (2015) 2.54
High expression of lymphocyte-associated genes in node-negative HER2+ breast cancers correlates with lower recurrence rates. Cancer Res (2007) 2.48
Predicting degree of benefit from adjuvant trastuzumab in NSABP trial B-31. J Natl Cancer Inst (2013) 2.28
Trastuzumab plus adjuvant chemotherapy for human epidermal growth factor receptor 2-positive breast cancer: planned joint analysis of overall survival from NSABP B-31 and NCCTG N9831. J Clin Oncol (2014) 2.24
Tumor antigen-targeted, monoclonal antibody-based immunotherapy: clinical response, cellular immunity, and immunoescape. J Clin Oncol (2010) 2.12
A compact VEGF signature associated with distant metastases and poor outcomes. BMC Med (2009) 1.84
Breast cancer, version 3.2013: featured updates to the NCCN guidelines. J Natl Compr Canc Netw (2013) 1.79
PI3K pathway activation results in low efficacy of both trastuzumab and lapatinib. BMC Cancer (2011) 1.73
Building prognostic models for breast cancer patients using clinical variables and hundreds of gene expression signatures. BMC Med Genomics (2011) 1.67
Effects of tissue handling on RNA integrity and microarray measurements from resected breast cancers. J Natl Cancer Inst (2011) 1.38
Oncogenic PI3K mutations lead to NF-κB-dependent cytokine expression following growth factor deprivation. Cancer Res (2012) 1.19
The immune system and response to HER2-targeted treatment in breast cancer. Lancet Oncol (2014) 1.17
Prognostic B-cell signatures using mRNA-seq in patients with subtype-specific breast and ovarian cancer. Clin Cancer Res (2014) 1.09
Potential biomarkers of long-term benefit from single-agent trastuzumab or lapatinib in HER2-positive metastatic breast cancer. Mol Oncol (2013) 1.00
Cellular adaptive immune system plays a crucial role in trastuzumab clinical efficacy. J Clin Oncol (2010) 0.90